Previous New Releases from NCBI BookshelfElexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta): Indication: Treatment of cystic fibrosis in patients aged 2 years and older who have at least one mutation in the CFTR gene that is responsive based on clinical and/or in vitro data: Reimbursement Recommendation [Internet].Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta): Indication: Treatment of cystic fibrosis in patients aged 2 years and older who have at least one mutation in the CFTR gene that is responsive based on clinical and/or in vitro data: Reimbursement Recommendation [Internet].
